A Phase 1 clinical trial has shown that CAR-T cell therapy can induce remission lasting 36 to 52 weeks in patients with severe rheumatoid arthritis, according to ad-hoc-news.de. The treatment was tested on patients who had exhausted other therapeutic options.
The trial, known as COMPARE, involved patients who had not responded to standard treatments. Results reported by multiple outlets, including aerzteblatt.de and it boltwise, indicate that the therapy produced drug-free remission in three patients. These individuals had previously been considered refractory to existing treatments, according to de.martincid.com.
CAR-T cell therapy involves reprogramming a patient's own immune cells to target specific disease markers. While the approach has gained prominence in oncology, this trial represents an early application to autoimmune disease. The findings, covered by medlabportal.de, suggest the therapy can dampen the overactive immune response driving rheumatoid arthritis without the need for ongoing medication.
The remission period observed in the study is notable because it extended beyond typical treatment windows. Patients remained symptom-free for roughly nine to twelve months after receiving the therapy, per the reporting. The trial's results were published around September 1, 2026, and have drawn attention from medical news outlets in Germany.
Researchers are likely to follow these patients to determine how long the remission persists and whether repeat dosing is needed. Larger trials will be necessary to confirm the safety and efficacy seen in this small Phase 1 study. The next step will be expanding the patient pool and tracking long-term outcomes.
